None listed
Conditions
Interventions
Procedure/Surgery : The standard prophylactic antiemetic, which is administered while administering high-emetogenic chemotherapy (HEC), will be used, and acupuncture will be added to it. All patients
Sponsors
Kyung Hee University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Those diagnosed with solid cancer - Male and female subjects over the age of 19 - Those receiving adjuvant therapy or palliative chemotherapy - Patients receiving high emetogenic (HEC) chemotherapy (HEC chemotherapy is defined as follows: i. cisplatin administration of = 50 mg/m2 of body surface area, ii. combination therapy of doxorubicin and cyclophosphamide, iii. cyclophosphamide administration of =1,500 mg/m2 of body surface area) - Those receiving chemotherapy for the first time - Physical activity performance (WHO performance status) 0~2 - Those who can take oral medications - Those who have adequate organ function and have no contraindications to chemotherapy (Absolute neutrophil count > 1,000/ul, platelets > 75,000/ul, liver enzyme levels less than 3 times the upper limit of normal, bilirubin < 2 mg/dL) - Those who have the cognitive ability to express spontaneous intentions and physical symptoms - Those who do not have a fear or rejection of acupuncture treatment - Those who have signed the informed consent form approved by the institutional review board
Exclusion criteria
Exclusion criteria: - patients who had clinical conditions that could cause nausea and vomiting other than chemotherapy, such as bowel obstruction, active gastrointestinal ulcer, and brain metastasis. - patients who received any type of acupuncture or who were taking daily medication that had antiemetic effects, such as steroids or benzodiazepines - any subject, regardless of the reason, who experienced nausea or vomiting in the week prior to study enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The intensity of delayed nausea, measured using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) from 24 h after the initial administration of chemotherapy to 120 hours post-administration | — |
Secondary
| Measure | Time frame |
|---|---|
| The intensity of delayed nausea, measured using the MASCC Antiemesis Tool (MAT) from 24 h after the initial administration of chemotherapy to 120 hours post-administration;The intensity of delayed vomiting and retching, measured using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) from 24 h after the initial administration of chemotherapy to 120 hours post-administration;The intensity of delayed nausea, measured using the MASCC Antiemesis Tool (MAT) from 24 h after the initial administration of chemotherapy to 120 hours post-administration;The intensity of acute nausea and vomiting, measured using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) from the the initiation to 24 hours after the chemotherapy.;The intensity of acute nausea and vomiting, measured using the MASCC Antiemesis Tool (MAT) from the the initiation to 24 hours after the chemotherapy.;Safery based on CTCAE v4.0 | — |
Countries
Korea, Republic of
Contacts
Public ContactChi Hoon Maeng
Kyung Hee University
Outcome results
None listed